Under the terms of the agreement, Orbit will deploy its bead-based peptide display engine to discover peptide leads specific to targets related to specific tumours.
Radioligand therapies rely on a simple concept: combining the ability of biological molecules such as peptides to target cancer cells with the short-range cell-killing capabilities of radioisotopes. This approach results in an increased cytotoxic potential toward cancer cells while limiting toxicity to nearby healthy cells. It opens new perspectives for patients with difficult to treat cancers and the global market of targeted radiotherapies is expected to grow at a CAGR of 30% between 2023 and 2030.
The collaboration will harness the capabilities of Orbit s peptide display engine to identify peptide candidates specific to tumour-associated targets. The proprietary technology enables the screening of large peptide collections through the combination of DNA encoded libraries and bead-based presentation. Orbit s peptide display engine is uniquely equipped to address soluble targets and targets in situ, both on and in cells, allowing for significantly faster discovery times of relevant peptide leads based on affinity screens and/or functional screens. Orano Med will focus on subsequent development of the peptides for clinical use after conjugation with lead-212, one of the most promising alpha emitter isotopes for use in radioligand therapy.
Dr
Julien Dodet, Chief Executive Officer, Orano Med, commented: Since the inception of Orano Med, we have recognised the value of collaboration. He added: In our strategy to develop and deliver 212Pb Targeted Alpha Therapy for cancer patients, we re delighted to work with Orbit Discovery and leverage its technology and expertise in peptide ligand discovery to build our pipeline of radiotherapies.
Orbit Discovery will be attending
About Orano Med SAS
Orano Med is a clinical-stage biotechnology company which develops a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), a rare alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha-Emitter Therapy (TAT). Alpha decay results in irreparable double strand DNA breaks in cells adjacent only to area of alpha emission, which leads to an increased cytotoxic potential toward cancer cells while limiting toxicity to nearby healthy cells. As a result, alpha emitters are considered as the most powerful payloads to be found for targeted therapies. Orano Med develops several treatments using 212Pb combined with various targeting agents. The company has 212Pb manufacturing facilities, laboratories, and R&D centers in
About Orbit Discovery
Orbit
Contact:
Web: www.orbitdiscovery.com
Tel: +44 (0) 1865 749234
(C) 2023 Electronic News Publishing, source